Syntara (ASX:SNT) Short Percentage of Float

View and export this data going back to 2003. Start your Free Trial

What is Syntara Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Syntara's Short Percentage of Float

For the Drug Manufacturers - Specialty & Generic subindustry, Syntara's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Syntara's Short Percentage of Float Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Syntara's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Syntara's Short Percentage of Float falls into.

Syntara Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Syntara Ltd (ASX:SNT) » Definitions » Short Percentage of Float

Comparable Companies

Traded in Other Exchanges

UUDA:Germany

Address

20 Rodborough Road, Unit 2, Frenchs Forest, Sydney, NSW, AUS, 2086

Website

https://www.syntaratx.com.au

Syntara Ltd is a clinical-stage drug development company working to bring new and life-changing treatments to patients in need. It is targeting extracellular matrix dysfunction with its expertise in amine oxidase chemistry and other technologies to develop novel medicines for blood cancers and conditions linked to inflammation and fibrosis. The company has various drug candidates in its pipeline such as SNT-5505, SNT-4728, SNT-5382, and SNT-8370 as a potential treatment for cancer, skin scarring, and neuroinflammation.